-
Sinovac Biotech’s SNA02-48 Gains Clinical Approval for Tetanus Prevention
•
Beijing Sinovac Biotech Co., Ltd’s (NASDAQ: SVA) subsidiary Sinovac Life Sciences Co., Ltd. and its partner Synermore Biologics announced that their Category I new drug, SNA02-48 injection, has received clinical approval from the National Medical Products Administration (NMPA). This recombinant fully human monoclonal antibody targets tetanus toxin and offers a…
-
Sinovac Partners with Brazil’s Fiocruz to Boost Vaccine Research and Development
•
Fiocruz, a renowned health research center based in Brazil, has announced a collaboration agreement with China’s Sinovac Biotech Ltd. (NASDAQ: SVA) to jointly engage in the research and development of vaccines. The financial details of the partnership have not been disclosed. This collaboration comes on the heels of a meeting…
-
Sinovac Biotech Commits USD 100 Million Investment in Brazil for Vaccine Research and Collaboration
•
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading vaccine specialist based in China, is reportedly set to invest USD 100 million in the Brazilian market to bolster collaborations with local partners and researchers. The company plans to conduct in-country research not only on vaccines but also on advanced therapeutics, including cell…
-
Sinovac Biotech Ltd Dismisses UK Private Equity’s Nominal Share Acquisition Offer
•
Sinovac Biotech Ltd (NASDAQ: SVA) has released a statement declaring that its board of directors has unanimously resolved to dismiss a nominal offer by UK-based private equity firm Alternative Liquidity Index LP to acquire up to 10 million of the company’s shares for USD 0.03 each. The board asserts that…
-
Sinovac Biotech Advances SA55 COVID-19 Neutralizing Antibody into Phase II Trials
•
China-based vaccines firm Sinovac Biotech Ltd (NASDAQ: SVA) has announced the completion of a Phase I trial and the immediate initiation of a Phase II study for its broad-spectrum COVID-19 neutralizing antibody, SA55. The molecule, which was first approved to enter clinical trials in China on May 24 this year,…
-
Sinovac Biotech Directors Reject Alternative Liquidity’s Lowball Tender Offer
•
China-based Sinovac Biotech Ltd. (NASDAQ: SVA) announced that its Board of Directors has unanimously determined that the partial tender offer by Alternative Liquidity Index LP to acquire up to 10,000,000 common shares of Sinovac for USD 0.03 apiece in cash is not advisable and is not in the best interests…
-
Sinovac Biotech Reports H1 2023 Financials with Significant Sales Decline from COVID-19 Boom
•
Sinovac Biotech Ltd (NASDAQ: SVA) has published its financial results for the first half of 2023, revealing a significant drop in sales from the COVID-19 surge experienced in the same period last year. Sales have fallen to USD 140.4 million, down from USD 1.2 billion in the first six months…
-
Sinovac Biotech Partners with Bogota to Establish BogotáBio for Vaccine Production
•
China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced a strategic partnership with Bogota, the capital of Colombia, to establish a joint venture named BogotáBio. The collaboration aims to strengthen local manufacturing capabilities for multiple vaccines and enhance novel vaccine research and development within the country. Colombia was one of the…
-
VACSERA in Talks with Sinovac to Establish Integrated Vaccine Plant
•
Egypt-based drug firm Holding Company for Biological Products and Vaccines (VACSERA) is reportedly in talks with China-based Sinovac Biotech Ltd (NASDAQ: SVA) to establish an integrated manufacturing plant focused on vaccines, according to a local media source. The proposed facility aims to enhance vaccine production capabilities and address the growing…
-
Sinovac Reports H1 2022 Financials Amid COVID-19 Vaccine Demand Decline
•
China-based Sinovac Biotech Ltd (NASDAQ: SVA) has released its financial report for the first half of 2022, ending on June 30, 2022. The firm reported revenues of USD 1.2 billion, a significant drop from the USD 11.0 billion recorded in the same period a year earlier. Net income attributable to…
-
WHO Approves Sinovac’s CoronaVac for Children Aged 3 and Above
•
The World Health Organization (WHO) has lowered the age limit for Sinovac Biotech Ltd’s (NASDAQ: SVA) COVID-19 vaccine, CoronaVac, to three years old. This makes it the first vaccine on the WHO’s Emergency Use List (EUL) to be approved for such a young age group and the only one recommended…
-
Sinovac Partners with Colombia University to Boost Vaccine R&D
•
China’s Sinovac (NASDAQ: SVA) has announced a partnership with Universidad de Antioquia of Colombia (UdeA) to collaborate on the construction of a vaccine research and development (R&D) center. The collaboration aims to enhance technical exchanges on vaccines and novel therapies, as well as to conduct basic research and translational studies…
-
Sinovac Biotech’s CoronaVac Receives Conditional Registration from South African Regulator
•
China-based Sinovac Biotech Ltd (NASDAQ: SVA) has announced that the South African Health Products Regulatory Authority (SAHPRA) has awarded conditional registration to the company’s COVID-19 vaccine CoronaVac. The approval permits the vaccine’s use in adults aged 18 and over, administered in two doses with a 14-28-day interval. Approval BackgroundThis conditional…
